C.A.P.A.B.L.E. (Cross-Training and Physical Activity: A Better Life Experience Study)
NCT03750981
Recruiting
This study will introduce cancer survivors to cross-training with the expectation that the program proposed will ultimately result in superior improvements in functional performance, body composition and quality of life compared with the current American Cancer Society (ACS) guidelines for cancer survivors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
Conditions: Cancer Survivors
Register for Updates
Evaluating BOSCC and ELSA as Outcome Measures in the Context of a JASPER Intervention Trial
NCT04146428
Recruiting
Research teams in Boston University, UCLA, and Weill Cornell will recruit 90 participants in 3 years (10 participants per site per year) and evaluate JASPER, play-based intervention, using the BOSCC and ELSA-T. Participants will be randomized to receive JASPER facilitated either by a clinician or the caregiver. After 10 weeks, the participants will be evaluated using the CGI to determine if they are "responders" or "non-responders". Nonresponders will be given a mix of clinician and caregiver-fa... Read More
Gender:
ALL
Ages:
Between 18 months and 5 years
Trial Updated:
05/21/2025
Locations: UCLA, Los Angeles, California +3 locations
Conditions: Autism Spectrum Disorder
Register for Updates
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
NCT04643002
Recruiting
The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the control Substudy. Substudies 02, 03, and 06 are controlled experimental substudies. Substudies 04 and 05 are independent experimental substudies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: University of Michigan Health System - Ann Arbor- Site Number : 8400004, Ann Arbor, Michigan +24 locations
Conditions: Plasma Cell Myeloma Refractory
Register for Updates
Matching Perfusion and Metabolic Activity in HFpEF
NCT04913805
Recruiting
This study will test whether pharmacologic agents that increase perfusion \[Potassium Nitrate (KNO3)\], with and without additional supplements that may improve mitochondrial function \[Propionyl-L-Carnitine (PLC) and Nicotinamide Riboside (NR)\], improve submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in participants with Heart Failure with Preserved Ejection Fraction (HFpEF).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Heart Failure With Preserved Ejection Fraction
Register for Updates
Investigation of Surgical Sectioning of the Filum Terminale in Treating Occult Tethered Cord Syndrome Patients
NCT05163899
Recruiting
The investigators hypothesize that surgical release of the filum terminale (strand of fibrous tissue at the end of the spinal cord) is a more efficacious treatment option for symptomatic relief than medical management in subjects with Occult Tethered Cord Syndrome (OTCS) and that the risks do not outweigh the benefit profile.
Gender:
ALL
Ages:
Between 2 years and 80 years
Trial Updated:
05/21/2025
Locations: Weill Cornell Medicine, New York, New York
Conditions: Tethered Cord, Tethered Cord Syndrome, Occult Spina Bifida, Spina Bifida Occulta
Register for Updates
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
NCT05263934
Recruiting
This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: GSK Investigational Site, Denver, Colorado +82 locations
Conditions: Eosinophilic Granulomatosis With Polyangiitis
Register for Updates
Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy
NCT05440643
Recruiting
This clinical research study investigates the safety, tolerability and efficacy of a peanut SLIT-tablet in adults, adolescents, and children with peanut allergy.
Gender:
ALL
Ages:
Between 4 years and 65 years
Trial Updated:
05/21/2025
Locations: Arkansas Children's Hospital, Little Rock, Arkansas +41 locations
Conditions: Peanut Allergy
Register for Updates
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
NCT05539430
Recruiting
This is a Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/21/2025
Locations: Moffitt Cancer Center, Tampa, Florida +7 locations
Conditions: Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer, Pancreatic Cancer
Register for Updates
Evaluating the Utility of RELiZORB™ for Treating Feeding Intolerance in Critically Ill Adults With Multi-Organ Failure
NCT05710315
Recruiting
The purpose of this research is to determine if the use of RELiZORB™ improves nutrition tolerance and helps critically ill patients meet their nutrition goals. RELiZORB™ is a digestive enzyme cartridge that contains lipase and works as a pancreatic enzyme replacement. It promotes breaking down fat and helps the body absorb it. The device connects with tube feedings to help the body with digestion. RELiZORB™ is approved by the U.S. Food and Drug Administration (FDA) for use with tube feedings in... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
05/21/2025
Locations: Inova Fairfax Medical Campus, Falls Church, Virginia
Conditions: Multi Organ Failure, Exocrine Pancreatic Insufficiency
Register for Updates
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
NCT05882877
Recruiting
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
05/21/2025
Locations: Cahaba Dermatology and Skin Health Center, Birmingham, Alabama +534 locations
Conditions: Atopic Dermatitis
Register for Updates
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
NCT05966467
Recruiting
Long-term, multicenter, multinational, observational, registry of patients with AQP4+ NMOSD that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT). The registry will also collect data on patient reported outcomes (PROs), quality of life (QoL), and targeted AQP4+ NMOSD therapies used to provide evidence on the real-world impact of ALXN-C5IT on patients with AQP4+ NMOSD.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Clinical Trial Site, Washington, District of Columbia +32 locations
Conditions: Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD
Register for Updates
19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease
NCT06066723
Recruiting
This study capitalizes on the emerging technology of 19F MRI, using conventional 'thermally' polarized perfluorinated gas (perfluoropropane, or PFP) mixed with oxygen and studied with magnetic resonance imaging (MRI) to visualize ventilation. This technique has not been studied in children. Children and adolescents (6-17 years old) with cystic fibrosis (CF) who have normal spirometry will undergo 19F MRI with the inhalation of an inert contrast gas to study ventilation. Comparisons will be made... Read More
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
05/21/2025
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Cystic Fibrosis in Children
Register for Updates